Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumor activity. MCL lines (Granta-519, Jeko-1, and Rec-1) were treated with escalating concentrations of bortezomib and fenretinide singly and in combination. Cytotoxicity was assessed using the MTT assay. Flow cytometric methods were used to assess apoptosis and necrosis, with annexin V-FITC/propidium iodide staining, and G1 and G2 cell-cycle changes were assessed by DAPI staining. Changes in cyclin D1, cyclin B, IκBα, and IKKα expressions were quantified by western blotting. Cytotoxicity was mediated through apoptosis; both agents showed observed versus expected cytotoxicities of 92.2 versus 55.1% in Granta-519, of 87.6 versus 36.3% in Jeko-1, and of 63.2 versus 29.8% in Rec-1. Isobolographic analysis confirmed synergy in Jeko-1 and Rec-1 cell lines. Bortezomib induced G2-phase arrest, with a 1.7-fold increase compared with control, and fenretinide resulted in G1-phase arrest, with an increase of 1.3-fold compared with control. In the combination, G2-phase arrest predominated, with a 1.4-fold increase compared with control, and there was reduced expression of cyclin D1 to 24%, cyclin B to 52 and 64%, cyclin D3 to 25 and 43%, IκBα to 23 and 46%, and IκBα kinase to 34 and 44%. Bortezomib and fenretinide exhibit synergistic cytotoxicity against MCL cell lines. This activity is mediated by IκBα kinase modulation, decreased cyclin expression, cell cycle dysregulation, and apoptotic cell death. Anti-Cancer Drugs 26:974-983
Background
Mantle cell lymphoma (MCL) is an aggressive disease, representing~6% of all lymphomas in the USA, with a median survival of greater than 5 years [1, 2] . The majority of patients with MCL are male and present at a median age of 68 years [2, 3] . The t(11;14)(q13;q32) chromosomal translocation is characteristic of MCL and juxtaposes the BCL1 gene with the immunoglobulin heavy chain gene locus, resulting in overexpression of cyclin D1 [4] . Although some patients have a clinically indolent disease, MCL is generally aggressive, with most patients demonstrating stage III or IV disease at diagnosis [2] . Historically, MCL has been associated with a poorer prognosis than many other aggressive lymphomas [2] . Over the last three decades, there has been a marked improvement in the management of patients with MCL, with advances in transplantation and the advent of targeted novel therapies, and driven by an improved understanding of the molecular biology of MCL. Typically, frontline management of MCL takes a risk-adapted strategy, reserving intensive high-dose therapy followed by autologous stem-cell transplantation for younger, fitter patients [2, 5] . The standard approach for elderly patients (defined as > 65 years old) is immunochemotherapy with bendamustine and rituximab, or rituximab and CHOP [cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone], followed by maintenance therapy with rituximab [2] . Other options include rituximab in combination with bendamustine, chlorambucil, or CVP (cyclophosphamide, vincristine, prednisone) [5] . Despite the efficacy of these regimens, MCL remains an incurable disease. Novel, improved treatments that maximize therapeutic benefits and minimize toxicities are needed.
Proteasome inhibitors (PI) were developed and studied in a wide variety of solid tumors and hematologic malignancies before clinical efficacy was demonstrated in multiple myeloma and MCL [5] . The proteasome is an important cellular component responsible for degradation of proteins involved in apoptosis and cell cycle regulation [6] . The initial phase II studies of single-agent bortezomib in MCL documented response rates between 38 and 55%, and a median time to progression of 6.2 months [7, 8] . The results from the phase II PINNACLE study were later updated to report an overall response rate of 33% and a median time to progression of 6.2 months, indicating that bortezomib-induced responses are generally not durable. [9] . Bortezomib, similar to other PIs, inhibits the 20S proteasome, resulting in accumulation of BH3-only proteins, which induce apoptosis in cancer cells [10] . The proposed mechanisms by which PIs cause cytotoxicity include production of reactive oxygen species, upregulation of Noxa, and reduction of autocrine signaling by interleukin (IL)-6 and IL-10, among others [11] [12] [13] . Bortezomib and other PIs, paradoxically, also induce calpain-mediated degradation of IκBα, resulting in increased nuclear factor-κB (NF-κB) activation and diminishing apoptosis [14] . Clinically, bortezomib is active at plasma concentrations of up to 0.5 μmol/l at typical doses [15] [16] [17] .
Retinoids are analogues of vitamin A and represent both synthetic and natural compounds, which have been examined extensively in the treatment of human malignancies. Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are two classes of receptors that the retinoid compounds are thought to act through, although retinoids also function in the absence of an identified receptor [18, 19] . Following dimerization, they act as liganddependent transcription factors, acting on various target genes. One such retinoid compound, N-(4-hydroxyphenyl) retinamide, also known as fenretinide, has been shown to be both anti-proliferative and proapoptotic in multiple preclinical studies using both solid tumor and hematologic malignancy cell lines [20] [21] [22] [23] [24] [25] . Although relatively weaker in binding to RARs and RXRs compared with other compounds in this class, fenretinide also modulates apoptosis through downregulation of IκBα kinase (IKK) and NF-κB gene products [26] , modulation of Bcl-2 [27, 28] , and caspase activation [29] . Fenretinide has also been studied in phase I and II human clinical trials in multiple solid tumors [30] [31] [32] [33] [34] [35] [36] [37] [38] . In these early-phase studies, plasma concentrations at peak and steady states were documented at 13 and 0.9-10 μmol/l, respectively [33, 39] .
We hypothesized that fenretinide could potentiate the antitumor activity of clinically attainable bortezomib concentrations in MCL lines through a common mechanism of antitumor activity -induction of apoptosis -and a shared pathway involving regulation of IκBα. We demonstrated that the combination of bortezomib and fenretinide revealed synergistic cytotoxic activity in all tested MCL lines, which appears to be mediated by modulation of IκBα kinase, cell cycle dysregulation through G2-phase arrest, decreased expression of cyclins D1, D3, and B, and apoptotic cell death.
Methods

Reagents and antibodies
Bortezomib was obtained from commercial sources (Millennium Pharmaceuticals, Cambridge, Massachusetts, USA). Fenretinide was provided by CTEP-NCI. Antibodies raised against IKKα, IKKβ, pIKKα/β, NF-κB p65, pNF-κB p65, IκBα, pIκBα, cyclin A, cyclin B1, cyclin D1, cyclin D2, cyclin D3, cyclin E, cyclin E2, cyclin H, and β-actin were purchased from Cell Signaling Technology (Danvers, Massachusetts, USA).
Cell lines
The human lymphoma cell lines Granta-519, Jeko-1, and Rec-1 were obtained from American Type Culture Collection (Rockville, Maryland, USA) as part of the Lymphoma Research Foundation Mantle Cell Lymphoma Cell Bank. Granta and Rec-1 were cultured in RPMI 1640 supplemented with 10% FBS and were incubated at 37°C with 5% CO 2 . Jeko-1 was cultured in RPMI 1640 supplemented with 20% FBS and was incubated under standard culture conditions.
In-vitro studies
Cells were incubated under standard culture conditions for 24 h at a concentration of 0.5 × 10 6 cells/ml in complete medium containing either diluent, bortezomib, fenretinide, or a combination. Following the incubation period, the cells were transferred to a 96-well plate or centrifuge tubes and prepared for cytotoxicity, apoptosis, and protein expression analyses. Data presented represent three independent experiments.
Cytotoxicity
Cytotoxicity was determined using the MTT assay as described previously [40] . Briefly, treated cells were seeded at a concentration of 5 × 10 5 cells/ml into a flatbottomed 96-well plate. Thiazolyl blue tetrazolium bromide (Sigma Aldrich, St Louis, Missouri, USA) was added to each well to a final concentration of 1 mg/ml. After a 2 h incubation period (37°C, 5% CO 2 ), 100 μl lysis buffer containing 50% DMF, 20% SDS, 2.5% 1 N HCl, and 2.5% of 80% acetic acid at pH 4.7 was added. The wells were mixed to dissolve the formazin crystals. The plate was read on a BioTek powerwave XS plate reader at 570 nm using Gen5 software.
Synergy analyses
A total of 5 × 10 4 cells were plated in a 96-well suspension culture plate. Bortezomib was added at concentrations ranging from 0 to 10 nmol/l. Fenretinide concentrations ranged from 0 to 15 μmol/l. The plates were incubated for 24 h. The MTT assay was performed, percent cytotoxic curves were plotted, and Biosoft software was used to determine synergy (Biosoft, Cambridge, UK).
Apoptosis
The FITC Annexin V Apoptosis kit from BD Pharmingen (BD, San Jose, California, USA) was used according to the directions provided with the kit. Briefly, 500 μl of cells were suspended in 1.5 ml centrifuge tubes. The cells were washed twice with PBS and resuspended in 100 μl 1 × binding buffer containing 5% annexin V-FITC and 5% propidium iodide. After 15 min of incubation, 250 μl of 1 × binding buffer was added and the samples were analyzed on the Guava minicyte flow cytometer (Guava, Hayward, California, USA).
Western blotting
Western blot analyses were carried out as previously described [41] , with β-actin used as a loading control. Briefly, cells were washed twice in cold PBS and lysed for 30 min on ice in a buffer containing 50 nmol/l Tris HCl (pH 7.4), 1% NP40, 0.25% sodium deoxycholate, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l phenylmethylsufonyl fluoride, 1 mmol/l sodium fluoride, 1% protease inhibitor cocktail, and 1% halt phosphatase (Thermo Scientific, Waltham, Massachusetts, USA). At the end of the incubation period, the cells were centrifuged for 10 min at 20 000g at 4°C, and the supernatant was collected and stored at − 80°C until the assay was performed. The supernatant was assayed for total protein using the BCA assay. A concentration of 35-50 μg of protein was loaded onto a 12% SDS gel and run for 2 h at 100 V. The proteins were transferred onto nitrocellulose membranes and detected using the antibodies listed above. The blots were immersed in SuperSignal West Pico chemiluminescent substrate (Thermo Scientific) and exposed to CL-Xposure film (Thermo Scientific), which was processed on a Kodak X-OMAT 2000 processor (Kodak, Rochester, New York, USA). The data were analyzed on ImageJ [42] .
Cell cycle
Following treatment, culture cells were centrifuged for 5 min. The supernatant was removed and 200 μl of a 10 μg/ml DAPI (Sigma) solution was added, and the cells were triturated using a 26 G needle attached to a 1 ml syringe. The cell solution was analyzed using BD LSR2 with an ultraviolet laser. The fractions of the cell population in the G1/G0, S, and G2 phases were quantified by applying the Dean-Jett-Fox model from FlowJo (Ashland, Oregon, USA), whereas the sub-G1 fraction was determined from the total event count.
Statistical analysis
All in-vitro data were collected from a minimum of three independent experiments. An analysis of variance was used to determine the statistical significance of differential findings between experimental and control groups in Graph-Pad Prism 3.0 software (Graph-Pad Software Inc., La Jolla, California, USA). The significance level was set at a two-tailed P-value of less than 0.05. Isobologram analyses were carried out with Biosoft software (Biosoft).
Results
Fenretinide demonstrated cytotoxicity in all tested mantle cell lymphoma lines in vitro
We performed an initial set of experiments to determine the degree of cytotoxic activity of fenretinide in Granta MCL cells. Fenretinide concentrations between 1 and 4 μmol/l were evaluated, and cytotoxicity was measured after In view of the data demonstrating single-agent cytotoxic activity, we tested the combination to evaluate potential synergy between fenretinide and bortezomib in MCL cell lines. Fenretinide concentrations varied between 1 and 15 μmol/l, in combination with bortezomib at concentrations of 3 nmol/l (Granta), 5 nmol/l (Jeko-1), and 10 nmol/l (Rec-1) -on the basis of prior data documenting physiologic, clinically active concentrations of both bortezomib and fenretinide, and reflecting relative resistance of each cell line to bortezomib [15] [16] [17] 33, 39] . These data were used to generate standard isobolograms and to calculate combination indices (CIs) to confirm synergy (Table 1 and Fenretinide and bortezomib demonstrated cytotoxic activity and induced apoptosis and necrosis in all tested mantle cell lymphoma lines in vitro Subsequent experiments examining the relative contributions of apoptosis and necrosis to the cell killing induced by the combination of bortezomib and fenretinide were designed using the optimal concentrations of the drugs identified in the isobolographic analysis. According to the MTT assay, bortezomib and fenretinide induced cytotoxic activity as single agents in Granta-519, Jeko-1, and Rec-1 MCL lines in vitro. Bortezomib alone at 3 nmol/l (Granta), 5 nmol/l (Jeko-1), and 10 nmol/l (Rec-1) concentrations induced cytotoxicity, with values of 12.8, 21.5, and 42.9%, for Granta, Jeko-1, and Rec-1 cell lines, respectively (Fig. 3 ). Fenretinide as a single agent yielded increased cytoxicity in this model at concentrations of 5 μmol/l (Granta and Rec-1) and 7.5 μmol/l (Jeko-1), with target cell death rates of 55.1, 36.3, and 29.8% for the respective cell lines. We demonstrated supra-additive activity between these agents when coincubated under the above conditions, with combined cytotoxicities of 92.2, 87.6, and 63.2% for the respective cell lines (Fig. 3) .
In view of the marked cytotoxicity seen with both singleagent and combination bortezomib and fenretinide, we next evaluated the relative contributions of apoptosis and necrosis to the cell killing observed in the MCL lines, using the Annexin V assay. Apoptosis after treatment with bortezomib was demonstrated in 34.1, 22.8, and 27.2% of Granta, Jeko-1, and Rec-1 cells, respectively (Fig. 3) . Treatment with fenretinide showed a similar trend, with apoptosis occurring in 62. Prior data have indicated that fenretinide can inhibit tumor necrosis factor-induced cyclin D1 expression [26] .
Whether the combination of fenretinide and bortezomib can decrease the levels of cyclin D1 further and whether other cell cycle regulators are also impacted were investigated; the results are depicted in Fig. 4 , along with images of the western blot assay used to perform the experiments. The concentrations of bortezomib used to address this question were 3 nmol/l (Granta), 5 nmol/l (Jeko-1), and 10 nmol/l (Rec-1), whereas the concentrations of fenretinide used were 5 μmol/l (Granta and Rec-1) and 7.5 μmol/l (Jeko-1). Bortezomib incubation alone did not change cyclin B1 levels; however, fenretinide reduced the fraction of cyclin B1 to 45% (Granta) and 70% (Jeko-1), and the combination of fenretinide and bortezomib reduced the cyclin B1 fraction to 52% (Granta) and 64% (Jeko-1). Similarly, whereas bortezomib did not induce a notable change in the cyclin D3 levels, fenretinide caused a drop in cyclin D3 levels to 72% in both Granta and Jeko-1 lines, and the combination yielded a reduction in cyclin D3 levels to 25% (Granta) and 43% (Jeko-1). In the Jeko-1 line, cyclin D1 levels were reduced to 59% by bortezomib, 77% by fenretinide, and 25% by the combination. No notable changes were observed in the expression of cyclin A or cyclin H after treatment with single agents or combinations. These results show that the combination of fenretinide and bortezomib decreased the expression levels of cyclin D1, cyclin D3, and cyclin B1.
The combination of fenretinide and bortezomib decreases expression of IκBα and IKK in vitro
We hypothesized that the combination of bortezomib and fenretinide would modulate both IκBα and IKK levels in vitro, consistent with previous findings [26] . The concentrations of bortezomib used to test this hypothesis were 3 nmol/l (Granta), 5 nmol/l (Jeko-1), and 10 nmol/l (Rec-1), whereas fenretinide was used at concentrations of 5 μmol/l (Granta and Rec-1) and 7.5 μmol/l (Jeko-1). Bortezomib resulted in a reduction of IκBα to 50 and 75% in Granta and Jeko-1 cell lines, respectively. The combination of fenretinide and bortezomib resulted in a reduction of IκBα to 23% in the Granta cell line and to 46% in the Jeko-1 cell line. Reductions in IKKα were also seen; the combination of bortezomib and fenretinide reduced the IKKα level to 34% in the Granta cell line and 44% in the Jeko-1 cell line. We found that the combination resulted in decreases in both IκBα and IKK levels (Fig. 4) .
The combination of fenretinide and bortezomib induced G2-phase arrest and increased the proportion of sub-G1 cells
Proceeding from data showing changes in the levels of expression of cell cycle modulators described previously, we hypothesized that the combination of both drugs could induce changes in the proportions of cells in different parts of the cell cycle. We tested Jeko-1 cells at 24 and 48 h with control, 5 nmol/l bortezomib, 7.5 μmol/l fenretinide, and a combination of 7.5 μmol/l fenretinide and 5 nmol/l bortezomib and carried out analysis using flow cytometry and DAPI. We verified that fenretinide increased the percentage of cells in the G1 phase of the cell cycle, whereas bortezomib caused G2 arrest. Together, the combination of agents induced predominantly G2-phase arrest. We observed that Jeko-1 cells showed an increase in G1 arrest by 1.3-fold compared with control when treated with fenretinide; G2-phase cells increased by 1.7-fold when the cells were incubated with bortezomib, and the combination of fenretinide and bortezomib resulted in a 1.4-fold increase in cells in the G2 phase, but no change in G1-phase cells (Fig. 5) .
We also showed that the combination of fenretinide and bortezomib increased the fraction of cells in the sub-G1 phase at both 24 and 48 h (Fig. 5) . At 24 and 48 h, respectively, control resulted in 5.6 and 5.8% of cells being in the sub G-1 phase, bortezomib alone resulted in 22.9 and 17.1% of cells being in the sub-G1 phase, fenretinide alone resulted in 24.8 and 24.68% of cells being in the sub-G1 phase, and the combination of fenretinide and bortezomib resulted in 28.88 and 43% of cells being in the sub-G1 phase.
Discussion
This study was performed to investigate the impact of fenretinide, bortezomib, and the combination of the two agents on cytotoxicity (apoptosis and necrosis), cell cycle regulation, and the NF-κB activation pathway. We found that bortezomib and fenretinide as single agents trigger cytotoxicity in vitro, as previously reported, and demonstrated that the combination exhibits synergism in MCL cell lines. This finding was confirmed by isobolographic analysis, carried out at concentrations of fenretinide that are physiologically administrable in humans [36] . We confirmed that the cytotoxicity was partially mediated by cell-cycle dysregulation, from inhibition of cyclin D1, cyclin D3, and cyclin B1. The degree of cyclin D1 inhibition seen with the combination was of particular interest, in view of the defining role of the t (11;14) translocation in the pathogenesis of MCL. Both necrosis and apoptosis played a role in fenretinide-mediated and bortezomib-mediated cytotoxicity. Similar to the findings of prior studies, bortezomib induced predominantly G2/ M-phase arrest, whereas fenretinide led to G1-phase arrest [43] [44] [45] . In combination, the two drugs yielded primarily G2-phase arrest, consistent with previous publications [44] .
Resistance to cell death, or evasion of apoptosis, is proposed as one of the central mechanisms underlying cancer development [46] . Bortezomib and fenretinide independently influence this pathway. Here, we have demonstrated that, in combination, there is impressive synergism in cytotoxicity. One potential explanation for the synergistic effect is shared modulation of the NF-κB pathway. Bortezomib is thought to act through inhibition of the 26S proteasome, preventing degradation of IκBα, resulting in decreased activation of NF-κB. In contrast, fenretinide is thought to act through multiple different mechanisms, including binding to the RAR and RXR receptors (albeit weakly); it also acts on the NF-κB pathway through suppression of NF-κB-dependent gene expression, inhibition of NF-κB activation, and inhibition of IKK [26] . Although bortezomib and fenretinide act in concert on the NF-κB pathway, fenretinide may also potentiate bortezomib through mitochondrial depolarization, which is known to induce apoptosis [18] .
Our findings confirm prior publications on the in-vitro effects of fenretinide and bortezomib. Here, we sought to further characterize the impact of this combination on MCL cell lines, a setting in which bortezomib as a single agent is relevant, whereas prior research has used metastatic melanoma and neuroblastoma cell lines [47, 48] . Our finding of synergy between these agents in MCL has been suggested previously through a report stating that physiologically attainable doses of fenretinide could be used with bortezomib to obtain improved suppression of TNF-induced NF-κB activation [26] . Although the capacity of fenretinide to inhibit tumor necrosis factordependent IκBα degradation has also been demonstrated, we have shown decreased expression of both IκBα and IKK with a combination bortezomib and fenretinide. This is in contrast to prior studies that have suggested that the inhibition of IκBα degradation is partially responsible for the mechanism of action of fenretinide. One potential explanation for this paradoxical finding is that bortezomib induces calpain-mediated degradation of IκBα and facilitate p65 nuclear translocation. We have shown that fenretinide reduces the expression of IKK, which may to some degree abrogate the effect that bortezomib has on calpain-mediated degradation of IκBα. Moreover, fenretinide has been shown to inhibit phosphorylation and nuclear translocation of p65, which may be responsible for mitigation of p65 activation seen with bortezomib, and for subsequent improvement of its cytotoxic effect [26] .
The combination of fenretinide and bortezomib induces impressive synergistic toxicity in MCL lines, which is related to different pathways that both agents act on to induce apoptosis in cancer cells. Although the therapeutic arena for non-Hodgkin lymphoma and, in particular, MCL has expanded rapidly in the recent years, this combination appears to have marked activity in MCL and warrants further investigation to provide new strategies for future treatments.
Conclusion
The combination of bortezomib and fenretinide is synergistically cytotoxic against MCL lines. This appears to be mediated by modulation of IKK and IκBα, cell cycle dysregulation, and apoptotic cell death. These findings, along with the moderate toxicity profile of bortezomib and fenretinide, support the clinical evaluation of such combinations for the treatment of MCL. The combination of these two agents is promising and warrants further evaluation in vivo and in clinical trials.
